Biopharmaceutical firm, Morphic Holding, Inc., has developed a range of oral small-molecule integrin therapeutics aimed at treating conditions such as autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Its lead product, MORF-057, specifically targets inflammation and is currently going through Phase 2 clinical trials to treat inflammatory bowel disease. The company's ongoing research includes the development of Next Gen a4ß7 Inhibitors for a wider range of gastro-intestinal (GI) indications such as EGIDs, pouchitis, among others, as well as avß8 for the treatment of Myelofibrosis and solid tumors, and fibronectin integrin for pulmonary hypertensive. The firm has a number of strategic alliances, including a license agreement with Janssen to discover and develop novel integrin therapeutics, a collaboration agreement with Schrödinger for integrin targets, and another license agreement with Children's Medical Center Corporation to commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding was founded in 2014 and has its headquarters in Waltham, Massachusetts.